# Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

> **NCT01888107** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag S.p.A.** · enrollment: 347 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Risperidone Long-acting Injectable (LAI) 25 mg
- **DRUG:** Risperidone LAI 37.5 mg
- **DRUG:** Risperidone LAI 50 mg

## Key facts

- **NCT ID:** NCT01888107
- **Lead sponsor:** Janssen-Cilag S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2013-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888107, "Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01888107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*